Literature DB >> 20646849

Three-dimensional analysis of recurrence patterns in rectal cancer: the cranial border in hypofractionated preoperative radiotherapy can be lowered.

Jasper Nijkamp1, Miranda Kusters, Regina G H Beets-Tan, Hendrik Martijn, Geerard L Beets, Cornelis J H van de Velde, Corrie A M Marijnen.   

Abstract

PURPOSE: The aim of this study was to determine whether and where the radiotherapy (RT) clinical target volume (CTV) could be reduced in short-course preoperative treatment of rectal cancer patients. METHODS AND MATERIALS: Patients treated in the Dutch total mesorectal excision trial, with a local recurrence were analyzed. For 94 (25 who underwent radiation therapy 69 who did not) of 114 patients with a local recurrence, the location of the recurrence was placed in a three-dimensionalthree (3D) model. The data in the 3D model were correlated to the clinical trial data to distinguish a group of patients eligible for CTV reduction. Effects of CTV reduction on dose to the small bowel was tested retrospectively in a dataset of 8 patients with three-field conformal plans and intensity-modulated RT (IMRT).
RESULTS: The use of preoperative RT mainly reduces anastomotic, lateral, and perineal recurrences. In patients without primary nodal involvement, no recurrences were found cranially of the S2-S3 interspace, irrespective of the delivery of RT. In patients without primary nodal involvement and a negative circumferential resection margin (CRM), only one recurrence was found cranial to the S2-S3 interspace. With a cranially reduced CTV to the S2-S3 interspace, over 60% reduction in absolute small bowel exposure at dose levels from 15 to 35 Gy could be achieved with three-field conventional RT, increasing to 80% when IMRT is also added.
CONCLUSIONS: The cranial border of the CTV can safely be lowered for patients without expected nodal or CRM involvement, yielding a significant reduction of dose to the small bowel. Therefore, a significant reduction of acute and late toxicity can be expected.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20646849     DOI: 10.1016/j.ijrobp.2010.01.046

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

Review 1.  The Perfect Total Mesorectal Excision Obviates the Need for Anything Else in the Management of Most Rectal Cancers.

Authors:  Richard John Heald; Ines Santiago; Oriol Pares; Carlos Carvalho; Nuno Figueiredo
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  Rectal cancer : when is the local recurrence risk low enough to refrain from the aim to prevent it?

Authors:  M L Sautter-Bihl; W Hohenberger; R Fietkau; C Rödel; H Schmidberger; R Sauer
Journal:  Strahlenther Onkol       Date:  2013-02       Impact factor: 3.621

3.  Mapping patterns of nodal metastases in esophageal carcinoma: rethinking the clinical target volume for supraclavicular nodal irradiation.

Authors:  Yijun Luo; Yuhui Liu; Xiaoli Wang; Bin Zhang; Jinming Yu; Chengang Wang; Yong Huang; Minghuan Li
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 4.  Current treatment of rectal cancer adapted to the individual patient.

Authors:  Laura Cerezo; Juan Pablo Ciria; Leire Arbea; Olga Liñán; Sergio Cafiero; Vincenzo Valentini; Francesco Cellini
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-03

Review 5.  Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?

Authors:  Juan Pablo Ciria; Mikel Eguiguren; Sergio Cafiero; Intza Uranga; Ivan Diaz de Cerio; Arrate Querejeta; Jose Maria Urraca; Julian Minguez; Elena Guimon; Jose Ramón Puertolas
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-26

6.  Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005.

Authors:  O Guerin; J Gal; E Francois; B Jacqueme; V Sciortino; J P Gerard
Journal:  Strahlenther Onkol       Date:  2012-03-14       Impact factor: 3.621

7.  Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective.

Authors:  Seo Hee Choi; Jee Suk Chang; Hong In Yoon; Dong-Su Jang; Nam Kyu Kim; Joon Seok Lim; Byung So Min; Hyuk Huh; Sang Joon Shin; Joong Bae Ahn; Woong Sub Koom
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-15       Impact factor: 4.553

Review 8.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

9.  Adenocarcinomas of the upper third of the rectum and the rectosigmoid junction seem to have similar prognosis as colon cancers even without radiotherapy, SAKK 40/87.

Authors:  S A Käser; J Froelicher; Q Li; S Müller; U Metzger; M Castiglione; U T Laffer; C A Maurer
Journal:  Langenbecks Arch Surg       Date:  2014-08-28       Impact factor: 3.445

Review 10.  Neo-adjuvant radiotherapy in rectal cancer.

Authors:  Bengt Glimelius
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.